Abstract：
We describe the substantial shortfall in adherence to guideline-recommended albumin-to-creatinine ratio (uACR) testing for people in the United States with type 2 diabetes. Poor compliance with current guidelines leads to delays in diagnosis-and treatment- of chronic kidney disease, which adversely affects clinical outcomes and contributes to incremental economic burden.
摘要：
我们描述了美国2型糖尿病患者在遵守指南推荐的白蛋白与肌酐比值（uACR）测试方面的严重不足。对当前指南的依从性差导致慢性肾脏疾病的诊断和治疗延迟，这会对临床结局产生不利影响，并增加经济负担。
